XNAS 02 Jan, 2026 4:30 PM (EST)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.55 per share. | 23 Dec 2025 | 5,500 | 55,269 (0%) | 0% | 3.5 | 19,514 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.55 per share. | 23 Dec 2025 | 5,500 | 55,269 (0%) | 0% | 3.5 | 19,514 | Common Stock |
| Kary Eldred | Director | Purchase of securities on an exchange or from another person at price $ 3.73 per share. | 23 Dec 2025 | 700 | 65,382 (0%) | 0% | 3.7 | 2,611 | Common Stock |
| Kary Eldred | Director | Purchase of securities on an exchange or from another person at price $ 3.73 per share. | 23 Dec 2025 | 700 | 65,382 (0%) | 0% | 3.7 | 2,611 | Common Stock |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2025 | 20,000 | 0 | - | - | Stock Option (right to buy) | |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 17 Dec 2025 | 20,000 | 31,206 (0%) | 0% | 2.0 | 39,600 | Common Stock |
| Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 7.04 per share. | 17 Dec 2025 | 19,793 | 11,206 (0%) | 0% | 7.0 | 139,303 | Common Stock |
| Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 7.04 per share. | 17 Dec 2025 | 4,706 | 6,500 (0%) | 0% | 7.0 | 33,121 | Common Stock |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.86 per share. | 17 Dec 2025 | 7,829 | 840,421 (1%) | 0% | 2.9 | 22,391 | Common Stock |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2025 | 7,829 | 32,171 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 7.06 per share. | 17 Dec 2025 | 7,829 | 832,592 (1%) | 0% | 7.1 | 55,241 | Common Stock |
| Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 17 Dec 2025 | 8,500 | 8,500 (0%) | 0% | 2.5 | 21,250 | Common Stock |
| Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.04 per share. | 17 Dec 2025 | 6,463 | 0 (0%) | 0% | 7.0 | 45,500 | Common Stock |
| Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.20 per share. | 17 Dec 2025 | 6,463 | 6,463 (0%) | 0% | 2.2 | 14,219 | Common Stock |
| Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.04 per share. | 17 Dec 2025 | 4,479 | 0 (0%) | 0% | 7.0 | 31,532 | Common Stock |
| Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 7.04 per share. | 17 Dec 2025 | 8,500 | 0 (0%) | 0% | 7.0 | 59,840 | Common Stock |
| Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2025 | 6,463 | 102,037 | - | - | Stock option (right to buy) | |
| Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Dec 2025 | 8,500 | 50,000 | - | - | Stock option (right to buy) | |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.16 per share. | 12 Dec 2025 | 8,417 | 19,623 (0%) | 0% | 4.2 | 35,015 | Common Stok |
| Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 6.27 per share. | 12 Dec 2025 | 19,793 | 11,206 (0%) | 0% | 6.3 | 124,181 | Common Stock |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.16 per share. | 12 Dec 2025 | 19,793 | 30,999 (0%) | 0% | 4.2 | 82,339 | Common Stock |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 8,417 | 0 | - | - | Stock option (right to buy) | |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2025 | 19,793 | 53,417 | - | - | Stock Option (right to buy) | |
| Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 6.30 per share. | 12 Dec 2025 | 8,417 | 11,206 (0%) | 0% | 6.3 | 53,027 | Common Stock |
| Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 08 Dec 2025 | 4,000 | 11,206 (0%) | 0% | 6.0 | 24,020 | Common Stock |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2025 | 16,790 | 73,210 | - | - | Stock Option (right to buy) | |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2025 | 20,000 | 20,000 | - | - | Stock Option (right to buy) | |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2025 | 35,000 | 35,000 | - | - | Stock Option (right to buy) | |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2025 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2025 | 20,000 | 20,000 | - | - | Stock option (right to buy) | |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2025 | 20,000 | 20,000 | - | - | Stock option (right to buy) | |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Dec 2025 | 35,000 | 35,000 | - | - | Stock option (right to buy) | |
| Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 6.27 per share. | 08 Dec 2025 | 16,790 | 11,206 (0%) | 0% | 6.3 | 105,206 | Common Stock |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.16 per share. | 08 Dec 2025 | 16,790 | 27,996 (0%) | 0% | 4.2 | 69,846 | Common Stock |
| Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 08 Dec 2025 | 20,000 | 11,206 (0%) | 0% | 6.0 | 120,040 | Common Stock |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 08 Dec 2025 | 20,000 | 31,206 (0%) | 0% | 1.1 | 22,200 | Common Stock |
| Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 6.02 per share. | 08 Dec 2025 | 35,000 | 11,206 (0%) | 0% | 6.0 | 210,665 | Common Stock |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 08 Dec 2025 | 35,000 | 46,206 (0%) | 0% | 2.1 | 73,850 | Common Stock |
| Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 5.95 per share. | 08 Dec 2025 | 25,000 | 11,206 (0%) | 0% | 5.9 | 148,650 | Common Stock |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.72 per share. | 08 Dec 2025 | 25,000 | 36,206 (0%) | 0% | 1.7 | 43,000 | Common Stock |
| Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 5.96 per share. | 08 Dec 2025 | 20,000 | 11,206 (0%) | 0% | 6.0 | 119,240 | Common stock |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 08 Dec 2025 | 20,000 | 31,206 (0%) | 0% | 2.0 | 39,600 | Common stock |
| Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 5.96 per share. | 08 Dec 2025 | 20,000 | 11,206 (0%) | 0% | 6.0 | 119,240 | Common Stock |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 08 Dec 2025 | 20,000 | 31,206 (0%) | 0% | 2.1 | 42,200 | Common Stock |
| Harold H. Shlevin | Director | Sale of securities on an exchange or to another person at price $ 5.95 per share. | 08 Dec 2025 | 35,000 | 11,206 (0%) | 0% | 6.0 | 208,250 | Common Stock |
| Harold H. Shlevin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.86 per share. | 08 Dec 2025 | 35,000 | 46,206 (0%) | 0% | 2.9 | 100,100 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 17 Nov 2025 | 9,586 | 17,200 (0%) | 0% | 2.0 | 18,980 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 18,190 | 0 | - | - | Common stock (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 28,120 | 0 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 2,323 | 48,750 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 19,701 | 18,190 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 9,586 | 28,120 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.22 per share. | 17 Nov 2025 | 18,210 | 7,614 (0%) | 0% | 6.2 | 113,321 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 17 Nov 2025 | 18,210 | 25,824 (0%) | 0% | 1.1 | 20,213 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.22 per share. | 17 Nov 2025 | 28,100 | 7,614 (0%) | 0% | 6.2 | 174,866 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 17 Nov 2025 | 28,100 | 35,714 (0%) | 0% | 2.0 | 55,638 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 17 Nov 2025 | 2,323 | 7,614 (0%) | 0% | 6.0 | 14,012 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 17 Nov 2025 | 2,323 | 9,937 (0%) | 0% | 1.2 | 2,857 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 17 Nov 2025 | 19,701 | 7,614 (0%) | 0% | 6.0 | 118,831 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 17 Nov 2025 | 19,701 | 27,315 (0%) | 0% | 1.1 | 21,868 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 17 Nov 2025 | 9,586 | 7,614 (0%) | 0% | 6.0 | 57,820 | Common stock |
| Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.04 per share. | 17 Nov 2025 | 15,680 | 832,592 (1%) | 0% | 6.0 | 94,643 | Common Stock |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 6,783 | 0 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Nov 2025 | 15,680 | 6,783 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.15 per share. | 17 Nov 2025 | 6,783 | 832,592 (1%) | 0% | 6.2 | 41,723 | Common Stock |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 17 Nov 2025 | 6,783 | 839,375 (1%) | 0% | 2.4 | 16,211 | Common Stock |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 17 Nov 2025 | 15,680 | 848,272 (1%) | 0% | 2.4 | 37,475 | Common Stock |
| Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.47 per share. | 13 Nov 2025 | 21,867 | 4,479 (0%) | 0% | 5.5 | 119,612 | Common Stock |
| Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.47 per share. | 13 Nov 2025 | 16,250 | 4,479 (0%) | 0% | 5.5 | 88,888 | Common stock |
| Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 41,500 | 58,500 | - | - | Stock option (right to buy) | |
| Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 13 Nov 2025 | 16,250 | 20,729 (0%) | 0% | 1.2 | 19,988 | Common stock |
| Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.47 per share. | 13 Nov 2025 | 41,500 | 4,479 (0%) | 0% | 5.5 | 227,005 | Common Stock |
| Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 16,250 | 48,750 | - | - | Stock option (right to buy) | |
| Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Nov 2025 | 41,500 | 108,500 | - | - | Stock option (right to buy) | |
| Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.50 per share. | 13 Nov 2025 | 41,500 | 45,979 (0%) | 0% | 2.5 | 103,750 | Common Stock |
| Khurram Jamil | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 5.47 per share. | 13 Nov 2025 | 41,500 | 4,479 (0%) | 0% | 5.5 | 227,005 | Common Stock |
| Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.20 per share. | 13 Nov 2025 | 41,500 | 45,979 (0%) | 0% | 2.2 | 91,300 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.02 per share. | 10 Nov 2025 | 1,880 | 7,614 (0%) | 0% | 6.0 | 11,321 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.23 per share. | 10 Nov 2025 | 1,736 | 9,350 (0%) | 0% | 1.2 | 2,135 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 10 Nov 2025 | 1,675 | 7,614 (0%) | 0% | 6.0 | 10,095 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 10 Nov 2025 | 1,675 | 9,289 (0%) | 0% | 1.1 | 1,859 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 10 Nov 2025 | 1,880 | 9,694 (0%) | 0% | 2.0 | 3,722 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 1,736 | 51,073 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 1,675 | 37,891 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 1,880 | 37,706 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 10 Nov 2025 | 1,736 | 7,614 (0%) | 0% | 6.0 | 10,468 | Common stock |
| Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 10 Nov 2025 | 1,867 | 832,592 (1%) | 0% | 6.0 | 11,252 | Common Stock |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2025 | 1,867 | 22,363 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 10 Nov 2025 | 1,867 | 834,459 (1%) | 0% | 2.4 | 4,462 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.72 per share. | 05 Nov 2025 | 200 | 7,814 (0%) | 0% | 1.7 | 344 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 05 Nov 2025 | 200 | 7,614 (0%) | 0% | 6 | 1,200 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 05 Nov 2025 | 200 | 7,814 (0%) | 0% | 1.1 | 222 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 05 Nov 2025 | 200 | 7,614 (0%) | 0% | 6 | 1,200 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 05 Nov 2025 | 200 | 7,814 (0%) | 0% | 2.0 | 396 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2025 | 200 | 52,809 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2025 | 200 | 39,566 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2025 | 200 | 39,586 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 05 Nov 2025 | 200 | 7,614 (0%) | 0% | 6 | 1,200 | Common stock |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Nov 2025 | 200 | 24,230 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 05 Nov 2025 | 200 | 832,592 (1%) | 0% | 6 | 1,200 | Common Stock |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 05 Nov 2025 | 200 | 832,792 (1%) | 0% | 2.4 | 478 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 03 Nov 2025 | 1,260 | 8,874 (0%) | 0% | 1.1 | 1,399 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.01 per share. | 03 Nov 2025 | 1,300 | 7,614 (0%) | 0% | 6.0 | 7,813 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 03 Nov 2025 | 1,300 | 8,914 (0%) | 0% | 2.0 | 2,574 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 10,741 | 53,009 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 8,974 | 39,766 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 8,914 | 39,786 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 1,250 | 63,750 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 1,260 | 48,740 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 1,300 | 48,700 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.07 per share. | 03 Nov 2025 | 10,741 | 7,614 (0%) | 0% | 6.1 | 65,198 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.72 per share. | 03 Nov 2025 | 10,741 | 18,355 (0%) | 0% | 1.7 | 18,475 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.07 per share. | 03 Nov 2025 | 8,974 | 7,614 (0%) | 0% | 6.1 | 54,472 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 03 Nov 2025 | 8,974 | 16,588 (0%) | 0% | 1.1 | 9,961 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.07 per share. | 03 Nov 2025 | 8,914 | 7,614 (0%) | 0% | 6.1 | 54,108 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 03 Nov 2025 | 8,914 | 16,528 (0%) | 0% | 2.0 | 17,650 | Common stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.01 per share. | 03 Nov 2025 | 1,250 | 7,614 (0%) | 0% | 6.0 | 7,513 | Commno stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.72 per share. | 03 Nov 2025 | 1,250 | 8,864 (0%) | 0% | 1.7 | 2,150 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.01 per share. | 03 Nov 2025 | 1,260 | 7,614 (0%) | 0% | 6.0 | 7,573 | Common Stock |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 14,420 | 24,530 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 03 Nov 2025 | 1,300 | 833,892 (1%) | 0% | 2.4 | 3,107 | Common Stock |
| Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.01 per share. | 03 Nov 2025 | 1,300 | 832,592 (1%) | 0% | 6.0 | 7,813 | Common Stock |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 03 Nov 2025 | 14,420 | 847,012 (1%) | 0% | 2.4 | 34,464 | Common Stock |
| Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.07 per share. | 03 Nov 2025 | 14,420 | 832,592 (1%) | 0% | 6.1 | 87,529 | Common Stock |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Nov 2025 | 1,300 | 38,950 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.37 per share. | 12 Sep 2025 | 8,706 | 16,320 (0%) | 0% | 1.4 | 11,927 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2025 | 8,706 | 0 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.44 per share. | 12 Sep 2025 | 8,706 | 7,614 (0%) | 0% | 6.4 | 56,054 | Common Stock |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 12 Sep 2025 | 14,000 | 846,592 (1%) | 0% | 2.4 | 33,460 | Common Stock |
| Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 6.36 per share. | 12 Sep 2025 | 14,000 | 832,592 (1%) | 0% | 6.4 | 89,048 | Common Stock |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2025 | 14,000 | 40,250 | - | - | Stock option (right to buy) | |
| Kary Eldred | Director | Purchase of securities on an exchange or from another person at price $ 2.92 per share. | 21 Jul 2025 | 1,000 | 64,682 (0%) | 0% | 2.9 | 2,925 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.90 per share. | 17 Jul 2025 | 5,000 | 49,769 (0%) | 0% | 2.9 | 14,495 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.57 per share. | 03 Mar 2025 | 56,420 | 832,592 (1%) | 0% | 1.6 | 88,579 | Common Stock |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 40,000 | 0 | - | - | Stock Option (right to buy) | |
| James C. Czirr | Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Feb 2025 | 10,000 | 731,416 (1%) | 0% | - | Common Stock | |
| James C. Czirr | Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Feb 2025 | 10,000 | 721,416 (1%) | 0% | - | Common Stock | |
| James C. Czirr | Ten Percent Owner | Other type of transaction at price $ 6.00 per share. | 03 Feb 2025 | 1,000 | 722,416 (1%) | 0% | 6 | 6,000 | Common Stock |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.89 per share. | 03 Feb 2025 | 31,250 | 753,666 (1%) | 0% | 0.9 | 27,813 | Common Stock |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 03 Feb 2025 | 46,875 | 800,541 (1%) | 0% | 2.4 | 112,031 | Common Stock |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.72 per share. | 03 Feb 2025 | 25,000 | 825,541 (1%) | 0% | 4.7 | 118,000 | Common Stock |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.86 per share. | 03 Feb 2025 | 30,000 | 855,541 (1%) | 0% | 2.9 | 85,800 | Common Stock |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 03 Feb 2025 | 40,000 | 895,541 (1%) | 0% | 2.1 | 84,400 | Common Stock |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.11 per share. | 03 Feb 2025 | 70,000 | 965,541 (1%) | 0% | 2.1 | 147,700 | Common Stock |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.98 per share. | 03 Feb 2025 | 40,000 | 1,005,541 (1%) | 0% | 2.0 | 79,200 | Common Stock |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.11 per share. | 03 Feb 2025 | 40,000 | 1,045,541 (1%) | 0% | 1.1 | 44,400 | Common Stock |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 31,250 | 291,875 | - | - | Stock Option (right to buy) | |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 46,875 | 245,000 | - | - | Stock Option (right to buy) | |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 25,000 | 220,000 | - | - | Stock Option (right to buy) | |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 30,000 | 190,000 | - | - | Stock Option (right to buy) | |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 40,000 | 150,000 | - | - | Stock Option (right to buy) | |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 70,000 | 80,000 | - | - | Stock Option (right to buy) | |
| James C. Czirr | Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Feb 2025 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Benjamin S. Carson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Gilbert S. Omenn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Gilbert S. Omenn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Restricted Stock Unit | |
| Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Kary Eldred | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 1.23 per share. | 23 Jan 2025 | 32,520 | 10,301,271 (18%) | 0% | 1.2 | 40,000 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 91,000 | 91,000 | - | - | Stock Option (right to buy) | |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 84,000 | 84,000 | - | - | Restricted Stock Unit | |
| Elissa J. Schwartz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Richard A. Zordani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| Khurram Jamil | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Khurram Jamil | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Restricted Stock Unit | |
| Harold H. Shlevin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 60,000 | 60,000 | - | - | Stock Option (right to buy) | |
| James C. Czirr | Ten Percent Owner | Other type of transaction at price $ 6.00 per share. | 31 Dec 2024 | 1,000 | 763,616 (1%) | 0% | 6 | 6,000 | Common Stock |
| James C. Czirr | Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2024 | 600 | 746,416 (1%) | 0% | - | Common Stock | |
| James C. Czirr | Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2024 | 5,000 | 741,416 (1%) | 0% | - | Common Stock | |
| James C. Czirr | Ten Percent Owner | Other type of transaction at price $ 6.00 per share. | 31 Dec 2024 | 1,000 | 747,016 (1%) | 0% | 6 | 6,000 | Common Stock |
| James C. Czirr | Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2024 | 4,400 | 746,016 (1%) | 0% | - | Common Stock | |
| James C. Czirr | Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2024 | 4,400 | 750,416 (1%) | 0% | - | Common Stock | |
| James C. Czirr | Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2024 | 4,400 | 754,816 (1%) | 0% | - | Common Stock | |
| James C. Czirr | Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2024 | 4,400 | 759,216 (1%) | 0% | - | Common Stock | |
| Shlevin H. Harold | Director | Purchase of securities on an exchange or from another person at price $ 1.16 per share. | 30 Dec 2024 | 6,500 | 15,206 (0%) | 0% | 1.2 | 7,540 | Common Stock |
| Kary Eldred | Director | Purchase of securities on an exchange or from another person at price $ 0.82 per share. | 24 Dec 2024 | 13,469 | 63,682 (0%) | 0% | 0.8 | 11,045 | Common Stock |
| Richard Zordani A. | Director | Purchase of securities on an exchange or from another person at price $ 0.82 per share. | 24 Dec 2024 | 10,000 | 42,083 (0%) | 0% | 0.8 | 8,164 | Common Stock |
| D. Freeman Kevin | Director | Purchase of securities on an exchange or from another person at price $ 0.81 per share. | 24 Dec 2024 | 10,000 | 44,769 (0%) | 0% | 0.8 | 8,134 | Common Stock |
| W. Callicutt Jack | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 40,000 | 47,614 (0%) | 0% | 0 | Common Stock | |
| Jamil Khurram | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 0.88 per share. | 23 Dec 2024 | 13,654 | 26,346 (0%) | 0% | 0.9 | 12,044 | Common Stock |
| Jamil Khurram | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 40,000 | 40,000 (0%) | 0% | 0 | Common Stock | |
| W. Jack Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.89 per share. | 23 Dec 2024 | 40,000 | 7,614 (0%) | 0% | 0.9 | 35,492 | Common Stock |
| Callicutt W. Jack | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 40,000 | 0 | - | - | Restricted Stock Units | |
| Lewis Joel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 56,000 | 0 | - | - | Restricted Stock Units | |
| Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 56,000 | 953,012 (1%) | 0% | 0 | Common Stock | |
| Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 40,000 | 0 | - | - | Restricted Stock Units | |
| Joel Lewis | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 0.89 per share. | 23 Dec 2024 | 56,000 | 897,012 (1%) | 0% | 0.9 | 49,610 | Common Stock |
| Kary Eldred | Director | Purchase of securities on an exchange or from another person at price $ 2.60 per share. | 23 Oct 2024 | 500 | 50,213 (0%) | 0% | 2.6 | 1,300 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.64 per share. | 17 Oct 2024 | 1,300 | 34,769 (0%) | 0% | 2.6 | 3,432 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.70 per share. | 16 Oct 2024 | 5,000 | 80,000 (0%) | 0% | 2.7 | 13,500 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.70 per share. | 16 Oct 2024 | 5,000 | 33,469 (0%) | 0% | 2.7 | 13,500 | Common Stock |
| Richard A. Zordani | Director | Purchase of securities on an exchange or from another person at price $ 2.30 per share. | 22 Aug 2024 | 741 | 30,324 (0%) | 0% | 2.3 | 1,704 | Common Stock |
| Richard A. Zordani | Director | Purchase of securities on an exchange or from another person at price $ 2.30 per share. | 22 Aug 2024 | 1,000 | 2,000 (0%) | 0% | 2.3 | 2,300 | Common Stock |
| Richard A. Zordani | Director | Purchase of securities on an exchange or from another person at price $ 2.30 per share. | 22 Aug 2024 | 1,759 | 32,083 (0%) | 0% | 2.3 | 4,046 | Common Stock |
| Khurram Jamil | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Khurram Jamil | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 10,000 | 10,000 | - | - | Restricted Stock Unit | |
| Kary Eldred | Director | Purchase of securities on an exchange or from another person at price $ 2.39 per share. | 22 Jul 2024 | 400 | 49,713 (0%) | 0% | 2.4 | 956 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.38 per share. | 20 Jun 2024 | 2,500 | 28,469 (0%) | 0% | 2.4 | 5,950 | Common Stock |
| Richard A. Zordani | Director | Purchase of securities on an exchange or from another person at price $ 3.52 per share. | 30 Apr 2024 | 1,000 | 1,000 (0%) | 0% | 3.5 | 3,520 | Common Stock |
| Joel Lewis | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 3.39 per share. | 24 Apr 2024 | 1,000 | 2,000 (0%) | 0% | 3.4 | 3,390 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.98 per share. | 22 Apr 2024 | 2,500 | 25,969 (0%) | 0% | 3.0 | 7,450 | Common Stock |
| James C. Czirr | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 3.06 per share. | 22 Apr 2024 | 3,677 | 5,922,207 (10%) | 0% | 3.1 | 11,252 | Common Stock |
| James C. Czirr | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 3.06 per share. | 22 Apr 2024 | 21,323 | 5,925,884 (10%) | 0% | 3.1 | 65,248 | Common Stock |
| Kevin D. Freeman | Director | 09 Apr 2024 | 2,063 | 18,063 (0%) | 0% | 0 | Common Stock | ||
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.96 per share. | 01 Mar 2024 | 152,584 | 897,716 (1%) | 0% | 2.0 | 299,065 | Common Stock |
| Omenn S. Gilbert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Uihlein Richard E. | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 1.72 per share. | 24 Jan 2024 | 23,256 | 10,268,751 (18%) | 0% | 1.7 | 40,000 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| Lewis Joel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 91,000 | 91,000 | - | - | Stock Option (right to buy) | |
| Eldred Kary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| F. Pol Boudes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 40,000 | 40,000 | - | - | Restricted Stock Unit | |
| J. Elissa Schwartz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| F. Boudes Pol | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 65,000 | 65,000 | - | - | Stock Option (right to buy) | |
| W. Callicutt Jack | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 40,000 | 40,000 | - | - | Restricted Stock Unit | |
| Zordani Richard A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Carson S. Benjamin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Gilbert Amelio F. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2024 | 56,000 | 56,000 | - | - | Restricted Stock Unit | |
| Eldred Kary | Director | Purchase of securities on an exchange or from another person at price $ 1.79 per share. | 16 Jan 2024 | 500 | 49,313 (0%) | 0% | 1.8 | 893 | Common Stock |
| James C. Czirr | Ten Percent Owner | Other type of transaction at price $ 6.00 per share. | 31 Dec 2023 | 1,000 | 762,616 (1%) | 0% | 6 | 6,000 | Common Stock |
| James C. Czirr | Ten Percent Owner | Other type of transaction at price $ 6.00 per share. | 31 Dec 2023 | 1,000 | 761,616 (1%) | 0% | 6 | 6,000 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.66 per share. | 29 Dec 2023 | 11,606 | 1,042,300 (1%) | 0% | 1.7 | 19,266 | Common Stock |
| Lewis Joel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.60 per share. | 15 Dec 2023 | 12,042 | 1,030,694 (1%) | 0% | 1.6 | 19,267 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.95 per share. | 30 Nov 2023 | 9,880 | 1,018,652 (1%) | 0% | 2.0 | 19,266 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.87 per share. | 15 Nov 2023 | 10,303 | 1,008,772 (1%) | 0% | 1.9 | 19,267 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.04 per share. | 31 Oct 2023 | 9,444 | 998,469 (1%) | 0% | 2.0 | 19,266 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.01 per share. | 13 Oct 2023 | 9,585 | 989,025 (1%) | 0% | 2.0 | 19,266 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.92 per share. | 29 Sep 2023 | 10,035 | 979,440 (1%) | 0% | 1.9 | 19,267 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 26 Sep 2023 | 1,466,204 | 9,466,495 (16%) | 2% | 5 | 7,331,020 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 26 Sep 2023 | 170,000 | 9,635,495 (16%) | 0% | 5 | 850,000 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2023 | 200,000 | 0 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2023 | 200,000 | 0 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2023 | 200,000 | 0 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2023 | 170,000 | 330,000 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Sep 2023 | 1,466,204 | 0 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.00 per share. | 26 Sep 2023 | 200,000 | 10,235,495 (17%) | 0% | 3 | 600,000 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 26 Sep 2023 | 200,000 | 10,035,495 (17%) | 0% | 3.3 | 652,000 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.00 per share. | 26 Sep 2023 | 200,000 | 9,835,495 (17%) | 0% | 3 | 600,000 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.76 per share. | 15 Sep 2023 | 10,947 | 969,405 (1%) | 0% | 1.8 | 19,267 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.75 per share. | 31 Aug 2023 | 11,010 | 958,458 (1%) | 0% | 1.8 | 19,268 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.60 per share. | 15 Aug 2023 | 12,042 | 947,448 (1%) | 0% | 1.6 | 19,267 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.50 per share. | 31 Jul 2023 | 12,844 | 935,406 (1%) | 0% | 1.5 | 19,266 | Common Stock |
| Kary Eldred | Director | Purchase of securities on an exchange or from another person at price $ 1.79 per share. | 19 Jul 2023 | 1,598 | 48,813 (0%) | 0% | 1.8 | 2,854 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.63 per share. | 14 Jul 2023 | 11,820 | 922,562 (1%) | 0% | 1.6 | 19,267 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.44 per share. | 30 Jun 2023 | 13,380 | 910 (0%) | 0% | 1.4 | 19,267 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.46 per share. | 15 Jun 2023 | 13,196 | 897,362 (1%) | 0% | 1.5 | 19,266 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.57 per share. | 31 May 2023 | 12,272 | 884,166 (1%) | 0% | 1.6 | 19,267 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.64 per share. | 15 May 2023 | 11,748 | 871,894 (1%) | 0% | 1.6 | 19,267 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.76 per share. | 28 Apr 2023 | 10,947 | 860,146 (1%) | 0% | 1.8 | 19,267 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.01 per share. | 14 Apr 2023 | 9,585 | 849,199 (1%) | 0% | 2.0 | 19,266 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.10 per share. | 31 Mar 2023 | 9,175 | 839,614 (1%) | 0% | 2.1 | 19,268 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.90 per share. | 15 Mar 2023 | 10,140 | 830,439 (1%) | 0% | 1.9 | 19,266 | Common Stock |
| Joel Lewis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.07 per share. | 28 Feb 2023 | 75,529 | 820,299 (1%) | 0% | 2.1 | 156,345 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.07 per share. | 28 Feb 2023 | 9,308 | 895,828 (1%) | 0% | 2.1 | 19,268 | Common Stock |
| Kary Eldred | Director | Purchase of securities on an exchange or from another person at price $ 1.59 per share. | 21 Feb 2023 | 1,000 | 47,215 (0%) | 0% | 1.6 | 1,591 | Common Stock |
| Joel Lewis | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 1.52 per share. | 16 Feb 2023 | 1,000 | 1,000 (0%) | 0% | 1.5 | 1,520 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.44 per share. | 15 Feb 2023 | 13,380 | 886,520 (1%) | 0% | 1.4 | 19,267 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.43 per share. | 07 Feb 2023 | 143,836 | 873,140 (1%) | 0% | 1.4 | 205,685 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.16 per share. | 31 Jan 2023 | 15,086 | 729,304 (1%) | 0% | 1.2 | 17,500 | Common Stock |
| James C. Czirr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Gilbert S. Omenn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Gilbert F. Amelio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Harold H. Shlevin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Pol F. Boudes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Kary Eldred | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 1.11 per share. | 26 Jan 2023 | 36,036 | 7,999,291 (14%) | 0% | 1.1 | 40,000 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Elissa J. Schwartz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Richard A. Zordani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2023 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Kary Eldred | Director | Purchase of securities on an exchange or from another person at price $ 1.11 per share. | 25 Jan 2023 | 1,300 | 46,215 (0%) | 0% | 1.1 | 1,443 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.14 per share. | 13 Jan 2023 | 15,351 | 714,218 (1%) | 0% | 1.1 | 17,500 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.13 per share. | 30 Dec 2022 | 15,487 | 698,867 (1%) | 0% | 1.1 | 17,500 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.16 per share. | 15 Dec 2022 | 15,086 | 683,380 (1%) | 0% | 1.2 | 17,500 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.27 per share. | 30 Nov 2022 | 13,780 | 668,294 (1%) | 0% | 1.3 | 17,501 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.32 per share. | 17 Nov 2022 | 4,000 | 7,614 (0%) | 0% | 1.3 | 5,280 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.24 per share. | 15 Nov 2022 | 14,113 | 654,514 (1%) | 0% | 1.2 | 17,500 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.38 per share. | 31 Oct 2022 | 12,681 | 640,401 (1%) | 0% | 1.4 | 17,500 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 1.41 per share. | 28 Oct 2022 | 10,000 | 75,000 (0%) | 0% | 1.4 | 14,100 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.62 per share. | 14 Oct 2022 | 10,802 | 627,720 (1%) | 0% | 1.6 | 17,499 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.63 per share. | 30 Sep 2022 | 10,736 | 616,918 (1%) | 0% | 1.6 | 17,500 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.79 per share. | 15 Sep 2022 | 9,777 | 606,182 (1%) | 0% | 1.8 | 17,501 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.90 per share. | 31 Aug 2022 | 9,211 | 596,405 (1%) | 0% | 1.9 | 17,501 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.18 per share. | 15 Aug 2022 | 8,028 | 587,194 (1%) | 0% | 2.2 | 17,501 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.26 per share. | 29 Jul 2022 | 7,743 | 552,139 (0%) | 0% | 2.3 | 17,499 | Common Stock |
| Richard A. Zordani | Director | Purchase of securities on an exchange or from another person at price $ 2.50 per share. | 28 Jul 2022 | 5,000 | 29,583 (0%) | 0% | 2.5 | 12,500 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.65 per share. | 15 Jul 2022 | 10,606 | 544,396 (0%) | 0% | 1.7 | 17,500 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.31 per share. | 30 Jun 2022 | 13,359 | 533,790 (0%) | 0% | 1.3 | 17,500 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.29 per share. | 15 Jun 2022 | 13,780 | 520,431 (0%) | 0% | 1.3 | 17,776 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.29 per share. | 31 May 2022 | 13,566 | 506,651 (0%) | 0% | 1.3 | 17,500 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 1.33 per share. | 19 May 2022 | 5,000 | 65,000 (0%) | 0% | 1.3 | 6,650 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.36 per share. | 13 May 2022 | 12,868 | 493,085 (0%) | 0% | 1.4 | 17,500 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.55 per share. | 29 Apr 2022 | 11,290 | 480,217 (0%) | 0% | 1.6 | 17,500 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 1.71 per share. | 18 Apr 2022 | 5,000 | 60,000 (0%) | 0% | 1.7 | 8,550 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.74 per share. | 15 Apr 2022 | 10,057 | 468,927 (0%) | 0% | 1.7 | 17,499 | Common Stock |
| Richard A. Zordani | Director | Purchase of securities on an exchange or from another person at price $ 1.60 per share. | 04 Apr 2022 | 5,000 | 24,583 (0%) | 0% | 1.6 | 8,025 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.61 per share. | 31 Mar 2022 | 10,870 | 458,870 (0%) | 0% | 1.6 | 17,501 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.74 per share. | 15 Mar 2022 | 10,057 | 448,000 (0%) | 0% | 1.7 | 17,499 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.87 per share. | 28 Feb 2022 | 9,358 | 437 (0%) | 0% | 1.9 | 17,499 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.07 per share. | 15 Feb 2022 | 8,454 | 428,585 (0%) | 0% | 2.1 | 17,500 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.93 per share. | 31 Jan 2022 | 112,263 | 420,131 (0%) | 0% | 1.9 | 216,668 | Common Stock |
| James C. Czirr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Gilbert S. Omenn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Gilbert F. Amelio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Harold H. Shlevin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Pol F. Boudes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Kary Eldred | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 1.98 per share. | 24 Jan 2022 | 17,677 | 7,936,677 (13%) | 0% | 2.0 | 35,000 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Elissa J. Schwartz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Richard A. Zordani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jan 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Elissa J. Schwartz | Director | Purchase of securities on an exchange or from another person at price $ 2.00 per share. | 21 Jan 2022 | 1,000 | 1,000 (0%) | 0% | 2 | 2,000 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 1.96 per share. | 19 Jan 2022 | 5,000 | 55,000 (0%) | 0% | 2.0 | 9,806 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.02 per share. | 14 Jan 2022 | 8,251 | 307,868 (0%) | 0% | 2.0 | 16,667 | Common Stock |
| Richard A. Zordani | Director | Purchase of securities on an exchange or from another person at price $ 2.02 per share. | 14 Jan 2022 | 5,000 | 19,583 (0%) | 0% | 2.0 | 10,100 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 15 Dec 2021 | 5,000 | 50,000 (0%) | 0% | 2.3 | 11,400 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.25 per share. | 15 Dec 2021 | 7,407 | 291,565 (0%) | 0% | 2.3 | 16,666 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.34 per share. | 06 Dec 2021 | 5,000 | 45,000 (0%) | 0% | 2.3 | 11,700 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.63 per share. | 30 Nov 2021 | 6,337 | 284,158 (0%) | 0% | 2.6 | 16,666 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.86 per share. | 15 Nov 2021 | 5,828 | 277,821 (0%) | 0% | 2.9 | 16,668 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.17 per share. | 29 Oct 2021 | 2,000 | 40,000 (0%) | 0% | 3.2 | 6,340 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.17 per share. | 29 Oct 2021 | 5,258 | 271,993 (0%) | 0% | 3.2 | 16,668 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.19 per share. | 21 Oct 2021 | 2,000 | 38,000 (0%) | 0% | 3.2 | 6,380 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.37 per share. | 19 Oct 2021 | 3,000 | 36,000 (0%) | 0% | 3.4 | 10,107 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.37 per share. | 15 Oct 2021 | 4,946 | 266,735 (0%) | 0% | 3.4 | 16,668 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.88 per share. | 30 Sep 2021 | 4,296 | 261,789 (0%) | 0% | 3.9 | 16,668 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.88 per share. | 23 Sep 2021 | 3,000 | 33,000 (0%) | 0% | 3.9 | 11,631 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2021 | 1,157,407 | 10,000,000 | - | - | Convertible Note | |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.73 per share. | 15 Sep 2021 | 4,468 | 257,493 (0%) | 0% | 3.7 | 16,666 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.93 per share. | 31 Aug 2021 | 4,241 | 253,025 (0%) | 0% | 3.9 | 16,667 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.38 per share. | 13 Aug 2021 | 4,931 | 248,784 (0%) | 0% | 3.4 | 16,667 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.75 per share. | 30 Jul 2021 | 6,061 | 243,853 (0%) | 0% | 2.8 | 16,668 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.59 per share. | 15 Jul 2021 | 6,435 | 237,792 (0%) | 0% | 2.6 | 16,667 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.20 per share. | 30 Jun 2021 | 5,208 | 231,357 (0%) | 0% | 3.2 | 16,666 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.50 per share. | 15 Jun 2021 | 4,762 | 226,149 (0%) | 0% | 3.5 | 16,667 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 3.97 per share. | 01 Jun 2021 | 4,198 | 221,387 (0%) | 0% | 4.0 | 16,666 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 4.23 per share. | 14 May 2021 | 3,940 | 217,189 (0%) | 0% | 4.2 | 16,666 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 4.42 per share. | 30 Apr 2021 | 3,771 | 213,249 (0%) | 0% | 4.4 | 16,668 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2021 | 2,000,000 | 10,000,000 | - | - | Convertible Note | |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.23 per share. | 15 Apr 2021 | 7,474 | 209,478 (0%) | 0% | 2.2 | 16,667 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.04 per share. | 05 Apr 2021 | 5,000 | 30,000 (0%) | 0% | 2.0 | 10,200 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.17 per share. | 31 Mar 2021 | 7,680 | 202,004 (0%) | 0% | 2.2 | 16,666 | Common Stock |
| James C. Czirr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| James C. Czirr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Gilbert S. Omenn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Gilbert S. Omenn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Gilbert F. Amelio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Gilbert F. Amelio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 50,000 | 50,000 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 100,000 | 100,000 | - | - | Stock option (right to buy) | |
| Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Harold H. Shlevin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Harold H. Shlevin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Pol F. Boudes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 100,000 | 100,000 | - | - | Stock option (right to buy) | |
| Pol F. Boudes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 50,000 | 50,000 | - | - | Stock option (right to buy) | |
| Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Kary Eldred | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Kary Eldred | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 140,000 | 140,000 | - | - | Stock option (right to buy) | |
| Elissa J. Schwartz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Elissa J. Schwartz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Richard A. Zordani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Richard A. Zordani | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Mar 2021 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.50 per share. | 15 Mar 2021 | 6,667 | 194,324 (0%) | 0% | 2.5 | 16,668 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.22 per share. | 05 Mar 2021 | 27,027 | 214,684 (0%) | 0% | 2.2 | 60,000 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.24 per share. | 26 Feb 2021 | 7,440 | 187,657 (0%) | 0% | 2.2 | 16,666 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.49 per share. | 15 Feb 2021 | 6,693 | 180,217 (0%) | 0% | 2.5 | 16,666 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 1.96 per share. | 29 Jan 2021 | 8,503 | 173,524 (0%) | 0% | 2.0 | 16,666 | Common Stock |
| Gilbert F. Amelio | Director | Sale of securities on an exchange or to another person at price $ 2.17 per share. | 11 Jan 2021 | 60,000 | 60,614 (0%) | 0% | 2.2 | 130,200 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.52 per share. | 15 Dec 2020 | 6,614 | 149,971 (0%) | 0% | 2.5 | 16,667 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.60 per share. | 30 Nov 2020 | 6,410 | 143,357 (0%) | 0% | 2.6 | 16,666 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.75 per share. | 13 Nov 2020 | 6,061 | 136,947 (0%) | 0% | 2.8 | 16,668 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.54 per share. | 30 Oct 2020 | 6,562 | 130,886 (0%) | 0% | 2.5 | 16,667 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.87 per share. | 15 Oct 2020 | 5,807 | 124,324 (0%) | 0% | 2.9 | 16,666 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.67 per share. | 30 Sep 2020 | 6,242 | 118,517 (0%) | 0% | 2.7 | 16,666 | Common Stock |
| Joel Lewis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 2.93 per share. | 15 Sep 2020 | 5,171 | 112,275 (0%) | 0% | 2.9 | 15,151 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 2.57 per share. | 04 Sep 2020 | 5,000 | 25,000 (0%) | 0% | 2.6 | 12,848 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.55 per share. | 04 Sep 2020 | 10,000 | 7,893,191 (13%) | 0% | 2.6 | 25,500 | Common Stock |
| Joel Lewis | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2020 | 250,000 | 250,000 | - | - | Stock option (right to buy) | |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 1.64 per share. | 19 Mar 2020 | 6,000 | 20,000 (0%) | 0% | 1.6 | 9,844 | Common Stock |
| Pol F. Boudes | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2020 | 300,000 | 300,000 | - | - | Stock option (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2020 | 46,875 | 0 | - | - | Stock option (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 13 Feb 2020 | 46,875 | 7,864,553 (13%) | 0% | 2.4 | 112,031 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.72 per share. | 13 Feb 2020 | 18,638 | 7,883,191 (13%) | 0% | 4.7 | 87,971 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2020 | 18,638 | 21,362 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2020 | 8,000 | 54,250 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 09 Feb 2020 | 8,000 | 107,104 (0%) | 0% | 2.4 | 19,120 | Common Stock |
| James C. Czirr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 30,000 | 30,000 | - | - | Stock option (right to buy) | |
| Gilbert S. Omenn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Gilbert F. Amelio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 50,000 | 50,000 | - | - | Stock option (right to buy) | |
| Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 30,000 | 30,000 | - | - | Stock option (right to buy) | |
| Harold H. Shlevin | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 45,000 | 45,000 | - | - | Stock option (right to buy) | |
| Kary Eldred | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 30,000 | 30,000 | - | - | Stock option (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 45,000 | 45,000 | - | - | Stock option (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 2.86 per share. | 09 Jan 2020 | 12,238 | 7,817,678 (13%) | 0% | 2.9 | 35,001 | Common Stock |
| Joel Lewis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jan 2020 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director | Grant, award, or other acquisition of securities at price $ 2.86 per share. | 09 Jan 2020 | 20,455 | 99,104 (0%) | 0% | 2.9 | 58,501 | Common Stock |
| James C. Czirr | Director | Other type of transaction at price $ 0.00 per share. | 31 Dec 2019 | 125,000 | 767,616 (1%) | 0% | - | Common Stock | |
| James C. Czirr | Director | Other type of transaction at price $ 6.00 per share. | 31 Dec 2019 | 1,000 | 892,616 (1%) | 0% | 6 | 6,000 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.36 per share. | 15 Nov 2019 | 3,000 | 14,000 (0%) | 0% | 3.4 | 10,076 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 3.71 per share. | 06 Sep 2019 | 1,290 | 11,000 (0%) | 0% | 3.7 | 4,786 | Common Stock |
| Gilbert F. Amelio | Director | Sale of securities on an exchange or to another person at price $ 3.30 per share. | 05 Sep 2019 | 30,000 | 124,614 (0%) | 0% | 3.3 | 99,000 | Common Stock |
| Harold H. Shlevin | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2019 | 8,706 | 29,294 | - | - | Stock option (right to buy) | |
| Harold H. Shlevin | Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.37 per share. | 04 Jun 2019 | 8,706 | 8,706 (0%) | 0% | 1.4 | 11,927 | Common Stock |
| Gilbert S. Omenn | Director | Purchase of securities on an exchange or from another person at price $ 4.28 per share. | 31 May 2019 | 18,578 | 66,769 (0%) | 0% | 4.3 | 79,514 | Common Stock |
| Gilbert S. Omenn | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 31 May 2019 | 61,929 | 61,929 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.28 per share. | 31 May 2019 | 2,354 | 3,614 (0%) | 0% | 4.3 | 10,075 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 31 May 2019 | 7,847 | 7,847 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 4.28 per share. | 31 May 2019 | 7,710 | 9,710 (0%) | 0% | 4.3 | 32,999 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 31 May 2019 | 25,700 | 25,700 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 31 May 2019 | 4,753 | 4,753 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 4.28 per share. | 31 May 2019 | 1,426 | 23,469 (0%) | 0% | 4.3 | 6,103 | Common Stock |
| Kary Eldred | Director | Purchase of securities on an exchange or from another person at price $ 4.28 per share. | 31 May 2019 | 3,033 | 44,415 (0%) | 0% | 4.3 | 12,981 | Common Stock |
| Kary Eldred | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 31 May 2019 | 10,110 | 10,110 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Joel Lewis | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 31 May 2019 | 42,831 | 42,831 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Joel Lewis | Director | Purchase of securities on an exchange or from another person at price $ 4.28 per share. | 31 May 2019 | 12,849 | 78,649 (0%) | 0% | 4.3 | 54,994 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 4.28 per share. | 29 May 2019 | 4,672,896 | 7,801,385 (13%) | 8% | 4.3 | 19,999,995 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 29 May 2019 | 500,000 | 3,128,489 (5%) | 0% | 5 | 2,500,000 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 4.28 per share. | 29 May 2019 | 7,710 | 27,710 (0%) | 0% | 4.3 | 32,999 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2019 | 15,576,322 | 15,576,322 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 May 2019 | 500,000 | 966,204 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2019 | 25,700 | 25,700 | - | - | Common Stock Purchase Warrant (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 4.82 per share. | 09 Apr 2019 | 20,700 | 2,628,489 (4%) | 0% | 4.8 | 99,851 | Common Stock |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 4.73 per share. | 05 Apr 2019 | 500 | 2,000 (0%) | 0% | 4.7 | 2,365 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 4.81 per share. | 05 Apr 2019 | 21,000 | 2,607,789 (4%) | 0% | 4.8 | 100,972 | Common Stock |
| Joel Lewis | Director | Purchase of securities on an exchange or from another person at price $ 4.82 per share. | 05 Apr 2019 | 667 | 65,800 (0%) | 0% | 4.8 | 3,214 | Common Stock |
| Marc Rubin | Director | Sale of securities on an exchange or to another person at price $ 6.02 per share. | 21 Feb 2019 | 859 | 13,581 (0%) | 0% | 6.0 | 5,175 | Common Stock |
| Marc Rubin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 21 Feb 2019 | 859 | 14,440 (0%) | 0% | 2.4 | 2,053 | Common Stock |
| Marc Rubin | Director | Sale of securities on an exchange or to another person at price $ 6.02 per share. | 21 Feb 2019 | 43,326 | 13,581 (0%) | 0% | 6.0 | 261,026 | Common Stock |
| Marc Rubin | Director | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 21 Feb 2019 | 7,000 | 13,581 (0%) | 0% | 6 | 42,000 | Common Stock |
| Marc Rubin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 21 Feb 2019 | 43,326 | 56,907 (0%) | 0% | 2.4 | 103,549 | Common Stock |
| Marc Rubin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2019 | 859 | 33,065 | - | - | Stock option (right to buy) | |
| Marc Rubin | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2019 | 43,326 | 33,924 | - | - | Stock option (right to buy) | |
| Kevin D. Freeman | Director | Purchase of securities on an exchange or from another person at price $ 4.29 per share. | 08 Feb 2019 | 1,500 | 1,500 (0%) | 0% | 4.3 | 6,428 | Common Stock |
| Joel Lewis | Director | Purchase of securities on an exchange or from another person at price $ 4.48 per share. | 07 Feb 2019 | 1,000 | 65,133 (0%) | 0% | 4.5 | 4,484 | Common Stock |
| Gilbert F. Amelio | Director | Sale of securities on an exchange or to another person at price $ 5.00 per share. | 30 Jan 2019 | 13,047 | 154,614 (0%) | 0% | 5 | 65,235 | Common Stock |
| Gilbert F. Amelio | Director | Sale of securities on an exchange or to another person at price $ 5.00 per share. | 30 Jan 2019 | 16,953 | 167,661 (0%) | 0% | 5 | 84,765 | Common Stock |
| Joel Lewis | Director | Purchase of securities on an exchange or from another person at price $ 4.80 per share. | 29 Jan 2019 | 1,000 | 64,133 (0%) | 0% | 4.8 | 4,805 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 4.87 per share. | 28 Jan 2019 | 48,500 | 2,586,789 (4%) | 0% | 4.9 | 236,244 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 4.77 per share. | 28 Jan 2019 | 3,000 | 2,538,289 (4%) | 0% | 4.8 | 14,315 | Common Stock |
| Gilbert F. Amelio | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.75 per share. | 21 Jan 2019 | 7,776 | 153,685 (0%) | 0% | 4.8 | 36,936 | Common Stock |
| Gilbert F. Amelio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2019 | 62,250 | 0 | - | - | Stock option (right to buy) | |
| Gilbert F. Amelio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2019 | 41,500 | 0 | - | - | Stock option (right to buy) | |
| Gilbert F. Amelio | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.75 per share. | 21 Jan 2019 | 31,322 | 184,614 (0%) | 0% | 4.8 | 148,780 | Common Stock |
| Gilbert F. Amelio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.39 per share. | 21 Jan 2019 | 62,250 | 215,935 (0%) | 0% | 2.4 | 148,778 | Common Stock |
| Gilbert F. Amelio | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.89 per share. | 21 Jan 2019 | 41,500 | 161,461 (0%) | 0% | 0.9 | 36,935 | Common Stock |
| James C. Czirr | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2019 | 25,000 | 25,000 | - | - | Stock option (right to buy) | |
| Gilbert S. Omenn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2019 | 35,000 | 35,000 | - | - | Stock option (right to buy) | |
| Gilbert F. Amelio | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2019 | 35,000 | 35,000 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2019 | 50,000 | 50,000 | - | - | Stock option (right to buy) | |
| Marc Rubin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2019 | 25,000 | 25,000 | - | - | Stock option (right to buy) | |
| Harold H. Shlevin | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2019 | 70,000 | 70,000 | - | - | Stock option (right to buy) | |
| Kevin D. Freeman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2019 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Kary Eldred | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2019 | 25,000 | 25,000 | - | - | Stock option (right to buy) | |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 4.72 per share. | 16 Jan 2019 | 7,415 | 2,535,289 (4%) | 0% | 4.7 | 34,999 | Common Stock |
| Richard E. Uihlein | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2019 | 40,000 | 40,000 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2019 | 35,000 | 35,000 | - | - | Stock option (right to buy) | |
| Joel Lewis | Director | Grant, award, or other acquisition of securities at price $ 4.72 per share. | 16 Jan 2019 | 11,653 | 63,133 (0%) | 0% | 4.7 | 55,002 | Common Stock |
| Stephen Shulman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2019 | 25,000 | 25,000 | - | - | Stock option (right to buy) | |
| James C. Czirr | None | Other type of transaction at price $ 6.00 per share. | 31 Dec 2018 | 1,000 | 890,630 (2%) | 0% | 6 | 6,000 | Common Stock |
| James C. Czirr | None | Other type of transaction at price $ 6.00 per share. | 31 Dec 2018 | 1,000 | 891,630 (2%) | 0% | 6 | 6,000 | Common Stock |
| Kary Eldred | None | Purchase of securities on an exchange or from another person at price $ 6.10 per share. | 25 Sep 2018 | 2,000 | 41,382 (0%) | 0% | 6.1 | 12,200 | Common Stock |
| Gilbert S. Omenn | None | Sale of securities on an exchange or to another person at price $ 6.03 per share. | 07 Sep 2018 | 11,000 | 56,561 (0%) | 0% | 6.0 | 66,365 | Common Stock |
| Gilbert S. Omenn | None | Sale of securities on an exchange or to another person at price $ 6.00 per share. | 07 Sep 2018 | 8,370 | 48,191 (0%) | 0% | 6 | 50,220 | Common Stock |
| Marc Rubin | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2018 | 6,000 | 16,500 | - | - | Stock option (right to buy) | |
| Marc Rubin | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Sep 2018 | 6,000 | 32,481 (0%) | 0% | 0 | Common Stock | |
| Marc Rubin | None | Sale of securities on an exchange or to another person at price $ 6.58 per share. | 04 Sep 2018 | 11,900 | 20,581 (0%) | 0% | 6.6 | 78,256 | Common Stock |
| Marc Rubin | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2018 | 29,000 | 22,500 | - | - | Stock option (right to buy) | |
| Marc Rubin | None | Sale of securities on an exchange or to another person at price $ 6.08 per share. | 30 Aug 2018 | 58,100 | 26,481 (0%) | 0% | 6.1 | 353,312 | Common Stock |
| Marc Rubin | None | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2018 | 29,000 | 84,581 (0%) | 0% | 0 | Common Stock | |
| Joel Lewis | None | Purchase of securities on an exchange or from another person at price $ 7.06 per share. | 25 Jun 2018 | 1,000 | 51,480 (0%) | 0% | 7.1 | 7,058 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.41 per share. | 19 Jun 2018 | 102,733 | 103,993 (0%) | 0% | 4.4 | 453,053 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2018 | 26,000 | 0 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2018 | 97,267 | 0 | - | - | Stock option (right to buy) | |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 8.08 per share. | 19 Jun 2018 | 97,267 | 1,260 (0%) | 0% | 8.1 | 786,034 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.41 per share. | 19 Jun 2018 | 97,267 | 98,527 (0%) | 0% | 4.4 | 428,947 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.01 per share. | 19 Jun 2018 | 128,733 | 1,260 (0%) | 0% | 9.0 | 1,159,987 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.45 per share. | 19 Jun 2018 | 26,000 | 129,993 (0%) | 0% | 3.5 | 89,700 | Common Stock |
| Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2018 | 102,733 | 97,267 | - | - | Stock option (right to buy) |